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Letter to the editor regarding “Efficacy of adding ramipril (VAsotop) to the 
combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with 
mitral valve degeneration: The VALVE trial” 
Abstract 
The manuscript entitled Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) 
and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial1 reports a study 
which sought to answer the question “could pimobendan be all that is needed beyond loop diuretics to 
manage congestive heart failure (CHF) in myxomatous mitral valve disease (MMVD)?” This was done by 
prospectively comparing the efficacy of pimobendan + ramipril + furosemide (triple treatment) to 
pimobendan + furosemide (double treatment) to treat new‐onset CHF caused by MMVD. 
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L E T T E R T O TH E E D I T O R
Letter to the editor regarding “Efficacy of adding ramipril
(VAsotop) to the combination of furosemide (Lasix) and
pimobendan (VEtmedin) in dogs with mitral valve
degeneration: The VALVE trial”
Dear Editors,
The manuscript entitled Efficacy of adding ramipril (VAsotop) to the
combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs
with mitral valve degeneration: The VALVE trial1 reports a study which
sought to answer the question “could pimobendan be all that is
needed beyond loop diuretics to manage congestive heart failure
(CHF) in myxomatous mitral valve disease (MMVD)?” This was done
by prospectively comparing the efficacy of pimobendan + ramipril
+ furosemide (triple treatment) to pimobendan + furosemide (double
treatment) to treat new-onset CHF caused by MMVD.
While agreeing with the authors that this question has merit, we
share several comments and questions regarding applicability of their
study results to current practice. During the VALVE trial, worsening
signs of CHF were primarily managed with progressively larger
diuretic dosages, as opposed to other potential pharmacological inter-
ventions such as greater renin-angiotensin-aldosterone system
(RAAS) suppression, alternative diuretic use, higher pimobendan dos-
ing, and arterial vasodilator treatment. While the angiotensin-
converting enzyme inhibitor (ACEI) ramipril (VASOTOP) was begun at
a once daily dosage according to label recommendation, the initial
furosemide dosage (median, 8 mg/kg/d), high by current clinical stan-
dards, was increased to as much as 15 mg/kg/d, before predefined
treatment failure was reached; ramipril dosage was increased (dou-
bled) in only 3 dogs. Spironolactone dosing was left to the clinicians'
discretion (added to baseline treatment in only 13 dogs, 8 in the triple
treatment group, and 5 dogs in the double treatment group).
The VALVE trial did not assess the efficacy of RAAS suppression
using biomarkers. Therefore, the question of whether ramipril ade-
quately or optimally suppressed RAAS, while failing to improve sur-
vival in the face of these diuretic dosages, remains unanswered.
We are also concerned that dogs in both treatment groups
received ACEI for an average of 9 months before entering the study
(44% of triple treatment group vs 26% of double treatment group;
P = .02), indicating that over one-quarter of the double treatment
group (the no ACEI group) previously had received an ACEI—and for a
duration longer than the median 7.6 months that these dogs remained
in the study. This is important because it is known that RAAS suppres-
sion before the onset of CHF has favorable effects on cardiac
remodeling.2
Although unknowable by the authors at the time of the VALVE
trial design, other studies completed during the 10-year duration of
the VALVE trial have demonstrated significant benefit from greater,
longer, and more broad-spectrum RAAS suppression (eg, higher or
q12h ACEI dosing and mineralocorticoid antagonist [MRA] inclusion)
in treating proteinuria and CHF.3-5
Because the VALVE trial was performed under Good Clinical
Practice guidelines, owner adherence to the trial protocol was quanti-
fied. It would be useful to know whether those measurements identi-
fied “adherence parity” between the 2 treatment groups, thus
eliminating 1 potential source of unintentional bias.
Ramipril, a narrow-spectrum RAAS suppressant (ie, it causes no
direct MRA effect), was tested as an “add-on” to drugs providing
symptomatic relief (pimobendan and furosemide). Although the
absence of an MRA as part of the test article is understandable
because of the timing of the VALVE study design, its absence impairs
our understanding of the potential role that true RAAS suppression
(ie, more RAAS suppression than ACE inhibition alone) might play in
managing CHF caused by MMVD. It is now known that incomplete
RAAS suppression (aldosterone breakthrough) is common with either
ACEI or angiotensin II receptor blockers (ARB) in normal dogs chal-
lenged with furosemide or amlodipine5,6; with ACEI in natural MMVD
before CHF (without furosemide)5,7; and in MMVD with CHF in dogs
receiving ACEI and furosemide.5,7 Furthermore, inclusion of MRAs in
therapeutic protocols has improved survival in CHF caused by
MMVD.3,5
Although it has not been directly investigated, it is likely that
the high doses of furosemide used in the VALVE Trial, with greater
RAAS stimulatory potential, enhanced the propensity for aldoste-
rone breakthrough.8 In dogs treated with ACEI and ARBs, there is an
estimated 30% to 40% incidence of aldosterone breakthrough at
conventional furosemide dosages, and a proportional clinical benefit
is seen with broad-spectrum RAAS suppression.3,5-7,9 For this
Received: 11 January 2021 Accepted: 12 January 2021
DOI: 10.1111/jvim.16035
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC. on behalf of the American College of Veterinary Internal Medicine.
J Vet Intern Med. 2021;1–2. wileyonlinelibrary.com/journal/jvim 1
reason, it would be important to know the average maximum furose-
mide dosage received, as well as the number of dogs that experi-
enced renal compromise, were euthanized, or exited the study for
polyuria and polydipsia or worsening renal dysfunction.
It would also be relevant to know the number of cases accrued
from each institution, as well as the average furosemide dosage, num-
ber of dogs receiving spironolactone or doubled ramipril dosage, and
how these potential institutional differences were accounted for dur-
ing data analysis. A large number of cases from a single center may
diminish the benefits of a multicenter study design or raise the possi-
bility of unintentional institutional acquisition bias.
Although the VALVE results are surprising and interesting, a con-
clusion that they obviate the need for ACEI treatment in the manage-
ment of CHF from MMVD is not justified. We believe this study to be
hypothesis generating, rather than pivotal. A larger study, employing
methodology that provides evidence of more complete RAAS inhibi-
tion with contemporary adjunctive heart failure treatment is needed
to provide pivotal data upon which to guide practice.
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